Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. - Wikidata - awgldk - TriplyDB

Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.

Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.

http://www.wikidata.org/entity/Q43888363

about

Biosimilars in the management of neutropenia: focus on filgrastim Hematopoietic stem and progenitor cell harvesting: technical advances and clinical utility Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.A dimeric peptide with erythropoiesis-stimulating activity uniquely affects erythropoietin receptor ligation and cell surface expression.Tbo-Filgrastim: A Review in Neutropenic Conditions.Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question.Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders.Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.Sesamol ameliorates radiation induced DNA damage in hematopoietic system of whole body γ-irradiated mice.Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.

P2860

Q26764906-EC6B95A1-11FE-4105-8B24-AFF2003347C7 Q27012881-F81A46D8-06D4-4DF1-9991-98C42A9A024A Q27013577-361F9A72-9F89-4FCD-953B-D947407A8A4B Q34486159-3323E743-6793-45D5-A3AD-E1066A7A1D48 Q35835005-E374A9A6-11B8-4E84-964F-3B70BD884AFE Q38186025-7304522F-2E27-464B-BE45-AF14A80BD178 Q38193590-BDC379FE-AD86-4E5A-A74D-C0D65DE201BB Q38771395-64495037-B42D-425A-9539-A78678E08006 Q38792513-2213DD40-836D-476D-B5AE-63E235375C04 Q38969947-3AF9D1B3-E3FD-4B8F-9A0B-244FC5B04257 Q39504419-3E938BBE-DDB0-4D74-8648-1CBA9FE9200E Q40402240-C7A9F90D-2070-4F25-8105-23F5E619CC7D Q45735258-7EC5D957-6179-4AE5-A565-C8B8F687B029 Q46922809-25D3B236-4762-476A-BD13-CDAC14E42472 Q47235713-6F997711-3116-44D1-84D1-9E9288801001 Q51149892-81901EC0-7F0E-4D46-ADF9-A319C203FF52 Q51832847-0EC69D58-CB54-421E-B710-AA480D8E8C0E Q53426777-385EFBDF-608E-487F-A7D8-4150B38851EE

P2860

Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.

http://www.wikidata.org/entity/Q43888363

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Use of a biosimilar granulocyt ...... mobilization and engraftment.

@en

Use of a biosimilar granulocyt ...... mobilization and engraftment.

@nl

type

label

Use of a biosimilar granulocyt ...... mobilization and engraftment.

@en

Use of a biosimilar granulocyt ...... mobilization and engraftment.

@nl

prefLabel

Use of a biosimilar granulocyt ...... mobilization and engraftment.

@en

Use of a biosimilar granulocyt ...... mobilization and engraftment.

@nl

P1433

Q43888363-A864FCC0-05DB-4A54-9E33-3B7A6983F864

P1476

Q43888363-2238D25D-0D55-4D12-A5C1-1AAE8811BA01

P2093

Q43888363-052138ED-CE85-4D9D-BADF-5BB6BB46EB66

Q43888363-3BC80AC0-6DC0-45D2-9E9F-6ADB06981DDD

Q43888363-537B0608-8AB3-4F25-90FA-D4FF1935D720

Q43888363-567BA007-2CA4-40E0-A5F1-5678A61A351F

Q43888363-5EFCAD10-8A3D-4D6B-AC78-DC731886D97A

Q43888363-6CA597C7-2D95-4FBB-99D0-480FDB2DA2C4

Q43888363-912C56BF-31F5-4F24-98F5-5EFDEBD7EA60

Q43888363-B19FE5AB-A675-4CAC-948A-9B2A63E5C5B8

Q43888363-D5A7F81E-540F-4FAC-BAFD-F926C93F7B7D

Q43888363-F1949D27-284E-4BA1-878A-1BD90B4D89C1

P2860

Q43888363-2B727C2F-B3C9-4B48-B4AE-5F36A262814B

Q43888363-4FC0AA4A-E953-40D1-9BA1-D5627D9EA678

Q43888363-81BEA817-0158-42C0-BB57-9C2BD82880F6

Q43888363-81F354DB-0C25-4CF1-B696-DA2C0088CE6D

Q43888363-88B1C679-FD2B-4008-A885-235C38CD4B69

Q43888363-ABFBBEC0-1495-4122-B050-F0226012BABA

Q43888363-B15C9A86-E06D-4A18-A9BB-15218B9657EC

P304

Q43888363-E1E6D222-9567-4EB8-8AF7-08BDE22D26B2

P31

Q43888363-627F4D50-D662-4565-B810-BA6EEB5B2F1B

P356

Q43888363-870CC078-ECB3-4656-ACB0-A29E492F718C

P407

Q43888363-4EB0972F-7841-4F6F-A8D2-54A5DD42ACF9

P433

Q43888363-6967E88B-7F4D-4B95-8218-2B4E444D910C

P478

Q43888363-AA3C9E77-F58F-462C-913F-A436800E5D17

P50

Q43888363-37111D78-9A9B-4A65-8E28-339F1E94ED3D

Q43888363-EE89954B-3EEF-4CF5-9EC8-96649D29D695

P577

Q43888363-19E76557-1E37-46E1-B9CF-5C2F14CF2424

P698

Q43888363-9D2D8F87-F0B0-4594-AFFB-BE3F14556F83

P356

P1433

British Journal of Haematology

P1476

Use of a biosimilar granulocyt ...... mobilization and engraftment.

@en

P2093

Amy Publicover

http://www.w3.org/2001/XMLSchema#string

Andrew Davies

http://www.w3.org/2001/XMLSchema#string

Carol Hurlock

http://www.w3.org/2001/XMLSchema#string

David Hutchins

http://www.w3.org/2001/XMLSchema#string

Deborah S Richardson

http://www.w3.org/2001/XMLSchema#string

Harriet Launders

http://www.w3.org/2001/XMLSchema#string

Jane Lamb

http://www.w3.org/2001/XMLSchema#string

Joan Newman

http://www.w3.org/2001/XMLSchema#string

Kate S Hill

http://www.w3.org/2001/XMLSchema#string

Matthew W Jenner

http://www.w3.org/2001/XMLSchema#string

P2860

Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals.

The challenge of biosimilars.

Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.

Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.

Utilization study of filgrastim (Neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients.

Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.

First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor

P304

107-111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12345

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

162

http://www.w3.org/2001/XMLSchema#string

P50

Peter W Johnson

P577

2013-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23614650

http://www.w3.org/2001/XMLSchema#string